This research, published in Haematologica (2020), investigates the role of the complement system—a key component of the innate immune response—in driving the severe inflammatory "cytokine storm" associated with COVID-19. By analyzing plasma biomarkers and conducting a compassionate-use trial of the C5 inhibitor Eculizumab, the study explores whether blocking the terminal complement pathway can mitigate COVID-induced organ damage.
Introduction
Early in the COVID-19 pandemic, clinical observations suggested that severe disease was driven less by direct viral toxicity and more by a dysregulated immune response. This hyper-inflammation often leads to acute respiratory distress syndrome (ARDS) and systemic coagulopathy. The authors hypothesized that the complement system, specifically the formation of the Membrane Attack Complex (MAC or sC5b-9), plays a central role in this pathology by damaging host cells and triggering thrombosis.
Methods and Patient Cohorts
The study analyzed 103 COVID-19 patients admitted to Saint-Louis Hospital in Paris, stratified by disease severity (moderate, severe, and critical) based on oxygen requirements.
Key methodologies included:
- Biomarker Quantification: Measuring circulating levels of C3, C4, and sC5b-9 via ELISA and nephelometry.
- Comparative Analysis: Comparing patient data against 68 healthy controls and 40 patients sampled two months post-discharge.
- Interventional Case Series: Eight high-risk patients with severe pneumonia received Eculizumab, a monoclonal antibody targeting C5, on a compassionate-use basis. Pharmacokinetics were monitored via CH50 levels and free drug concentrations.
Results: Complement Activation and Disease Severity
The study found systemic complement activation in 64% of hospitalized patients. A clear "severity gradient" was observed: sC5b-9 levels correlated directly with clinical worsening. Median sC5b-9 levels in COVID-19 patients were 344 ng/mL, significantly higher than the 160 ng/mL found in healthy controls ($P<0.0001$).
Notably, critical patients exhibited the highest levels of activation. In patients tested two months after discharge, sC5b-9 levels returned to baseline, confirming that the activation was an acute, infection-driven response.
Therapeutic Intervention: Eculizumab Case Series
In the interventional arm, eight patients with severe respiratory failure were treated with Eculizumab. The biochemical response was rapid, with median sC5b-9 levels dropping from 463 ng/mL pre-treatment to 317 ng/mL post-treatment ($P=0.01$).
The "Molecular Sink" Effect
A critical finding was the unique pharmacokinetics of Eculizumab in COVID-19. Patients appeared to "consume" the drug much faster than those with other complement-mediated diseases (like aHUS). This massive activation acts as a "molecular sink," necessitating higher or more frequent dosing (e.g., 1200mg every 4 days) to maintain a complete complement blockade.
Discussion and Clinical Implications
The data suggest a "vicious cycle" where complement activation promotes the formation of Neutrophil Extracellular Traps (NETs), which in turn drive the life-threatening blood clots frequently seen in severe cases.
While the clinical improvement in 6 out of 8 treated patients is promising, the authors acknowledge significant limitations, including the small sample size and the lack of a randomized control group. They conclude that while C5 inhibition is a viable therapeutic target, future clinical trials must account for the high drug clearance rates observed in COVID-19 to ensure efficacy.
Summary updated